March 2026
Our vision i to transform cancer care for patients
the
3
Veracyte Diagnostics Platform
Risk Assessment
Diagnosis
Prognosis
Treatment Guidance
Recurrence Monitoring
Leveraging our platform across the cancer care continuum
WOMEN'S HEALTH
Breast
ENDOCRINOLOGY
Thyroid
PULM ONO LOGY
Lung
TrueMRD MIBC
Bladder
UROLOGY
UROLOGY
With Decipher Prostate
UROLOGY
Prostate
UROLOGY
+
With Decipher Prostate
UROLOGY
Gray indicates pipeline tests 5
on g o
Our platform drives growth and scale
1. Total patients served with any Veracyte test inception through December 31, 2025; 2. Total publications utilizing any Veracyte test from inception through December 31, 2025
Further penetration and share gains
Launched Decipher for metastatic patients
Achieved >25% adj. EBITDA in 2025
Expanded Afirma and Decipher clinical evidence
Transitioned Afirma to v2 transcriptome
Completed Veracyte SAS restructuring
Completed NIGHTINGALE enrollment
7
How aggressive is my prostate cancer?
Does my cancer need treatment?
Will I need hormone therapy and for how long?
Do I need chemotherapy if I have metastatic disease?
8
Helping physicians provide personalized care
>300K
Patients tested to date1
~215M
Covered lives2
>15%
2025 increase in ordering providers compared to the prior year
Market leader for prostate cancer prognosis & prediction
1. Decipher patients tested from inception through December 31, 2025; 2. Decipher covered lives as of December 31, 2025 9
U.S. TAM
~334,000patients diagnosed with prostate cancer annually1
1. Company estimates based on 2026 ACS data 2. Company estimates as of December 31, 2025
Strong growth trajectory for Decipher following reimbursement
Annual Volume
~102K
2016
2011
ACQUIRED BY VERACYTE
2025
2016
2017
2018
2020
2021
2023
Q4 2024
Q2 2025
2025E
Biopsy launch
First GRID1 report
Initial NCCN2 guideline inclusion
Localized prostate cancer reimbursement
PREDICT-RT,
GUIDANCE trials begin accrual
NCCN2
recognizes Simon level 1B evidence
NCCN2
guideline updates
Metastatic launch
Research use only
Biopsy Medicare Reimbursement 11NCCN = National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way
Legend:
Accrual / Initiation In Analysis Published
Decipher clinical evidence continues to build
115
Decipher Prostate Publications
and growing
Low Risk Biopsy
Intermediate Risk Biopsy
High Risk Biopsy
Post-Radical Prostatectomy
Biochemically Recurrent Advanced Stage & Metastatic
12
Expand clinical signatures available on the Decipher report
For example, PORTOS, PTEN and PAM 50 to further enhance clinical insights
Drive continued penetration into advanced disease
with the launch of metastatic and the development of expanded clinical signatures to drive growth in high-risk, post surgery BCR and metastatic
Scan all slides to build digital pathology database
Currently >210,000 slides from
>150,000 patients with outcomes data for digital pathology research - representing the majority of the historical database on Decipher
13
Do I have cancer?
Should I have
surgery to remove this nodule?
What treatment options should
I consider?
14
Guiding informed thyroid nodule care at scale
>400KPatients tested to date1
>250KPatients spared unnecessary surgery2
~280MCovered lives3
>150Publications4
Market leader in molecular thyroid diagnostics
15
1. Afirma patients tested from inception through December 31, 2025; 2. Afirma patients spared unnecessary surgery from inception through December 31, 2025; 3. Afirma covered lives as of December 31, 2025; 4. Afirma publications as of December 31, 2025
U.S. TAM
~180,000
patients indeterminate, suspected or diagnosed with thyroid cancer1
1. Company estimates of the annual incidence of Bethesda III, IV, V and VI nodules based on market data as of the end of 2025 2. Company estimates as of December 31, 2025
Durable growth persists
more than a decade after launch
Annual Volume
>67K
2011 2025
2011
2012
2018
Q1 2023 Q1 2024
2025
Afirma GEC
Afirma GSC
TERT GRID1
v2 Transcriptome
1. Research use only
Medicare Reimbursement 17
23
Launch of Afirma GRID drives research
Launch of Afirma GRID
9
7
2023
2024
5
2022
2025
Afirma GSC focused Afirma GRID focused 18
Phased strategic growth drivers expand the reach of our platform near-term, mid-term & long-term
Prosigna®
IVDs
TrueMRD
Nasal Swab
19
Prosigna
What kind of breast cancer do I have?
Will my cancer come back?
Do I need chemotherapy?
*Transcriptome-based laboratory developed test io provide Prosigna score and intrinsic subtypes, also referred to as Prosigna LDT
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original document
- Permalink
Disclaimer
Veracyte Inc. published this content on March 03, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 03, 2026 at 13:14 UTC.
